Kite and Pregene Begin In Vivo BCMA CAR T Dosing in China

Company Kite (Gilead); Shenzhen Pregene Event Type First-patient dosing disclosure (earnings call) Modality In vivo CAR-T Asset In vivo BCMA CAR-T (investigator-initiated, China) Target BCMA Disease Area Multiple myeloma Summary On its 29 October earnings call Gilead said patients have begun dosing in a China…